Britain and America have reached a significant trade agreement that will ensure no levies on UK drug shipments entering the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the public health system. This pledge ensures that duties on these vital exports will stay at zero for a timeframe of 36 months.
This development comes after recent warnings to hike import taxes on patented pharmaceutical products, with potential rates floated up to double the cost.
"This arrangement with the UK strengthens the international landscape for innovative medicines and establishes long-overdue balance to transatlantic pharmaceutical trade," a release said.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's largest goods shipped to the America, which is clearly the primary market for major companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK exported drugs valued at £11.1bn to the US. This value accounted for 17.4% of all goods exports in that span.
"This agreement safeguards jobs, increases funding and facilitates the UK to become a worldwide center for biotech and pharma," a minister stated.
Specific NHS Changes
The deal entails several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, repayments exceeded twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
These tensions were intensified by arguments that US consumers were paying a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the last ten years.
